SRPK2调控前体mRNA选择性剪接在酒精性肝病脂质代谢中的机制研究进展

摘要/Abstract

摘要： 酒精性肝病是长期大量饮酒导致的主要疾病之一,有可能进展为肝硬化甚至肝癌。脂质代谢紊乱在酒精性肝病的发展中扮演着重要的角色。国内外研究尚未完全揭示酒精性肝病中脂质代谢紊乱机制。已有研究证实,SRPK2调控的前体信使RNA选择性剪接在酒精性肝病脂质代谢紊乱中发挥关键作用。本文就国内外文献进行综述,包括酒精性肝病中典型的脂质代谢紊乱机制以及选择性剪接的新机制,旨在为推动酒精性肝病的预防和治疗提供理论参考。

关键词: 酒精性肝病, 脂质代谢, SRPK2, 前体mRNA, 选择性剪接

韩潘十力, 冯悦, 高沿航. SRPK2调控前体mRNA选择性剪接在酒精性肝病脂质代谢中的机制研究进展[J]. 肝脏, 2024, 29(4): 380-383.

/ 推荐

参考文献

[1] Singal AK, Mathurin P. Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review[J]. JAMA, 2021,326(2):165-176.
[2] Huang DQ, Mathurin P, Cortez-Pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors[J]. Nat Rev Gastroenterol Hepatol,2023,20(1):37-49.
[3] Wu X, Fan X, Miyata T, et al. Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease[J]. Annu Rev Pathol,2023,18:411-438.
[4] You M, Arteel GE. Effect of ethanol on lipid metabolism[J]. J Hepatol,2019,70(2):237-248.
[5] Luo P, Zheng M, Zhang R, et al.S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling[J]. Acta Pharm Sin B,2021,11(3):668-679.
[6] Clugston RD, Yuen JJ, Hu Y,et al. CD36-deficient mice are resistant to alcohol-and high-carbohydrate-induced hepatic steatosis[J]. J Lipid Res,2014,55(2):239-246.
[7] Thoudam T, Chanda D, Lee JY, et al. Enhanced Ca²⁺-channeling complex formation at the ER-mitochondria interface underlies the pathogenesis of alcohol-associated liver disease[J]. Nat Commun, 2023,14(1):1703.
[8] Hyun J, Al Abo M, Dutta RK, et al. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease[J]. J Hepatol,2021,75(3):623-633.
[9] López-Cánovas JL, Hermán-Sánchez N, Del Rio-Moreno M, et al. PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing[J]. Exp Mol Med,2023, 55(1):132-142.
[10] Yang Z, Han S, Zhang T,et al. Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis[J]. Hepatol Commun,2022,6(6):1361-1372.
[11] Hyun J, Sun Z, Ahmadi AR, et al. Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis[J]. J Clin Invest,2020,130(4):2129-2145.
[12] Tufail M, Wu C. SRPKs: a promising therapeutic target in cancer[J]. Clin Exp Med,2023, 23(7):3093-3112.
[13] Nikolakaki E, Sigala I, Giannakouros T. Good Cop, Bad Cop: The Different Roles of SRPKs[J]. Front Genet,2022,13:902718.
[14] Pihlajamäki J, Lerin C, Itkonen P,et al. Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis[J]. Cell Metab,2011,14(2):208-218.
[15] Chen H, Shen F, Sherban A, et al. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease[J]. Hepatology,2018,68(2):496-514.
[16] Li G, Chen H, Shen F, et al. Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis[J]. Hepatology,2023, 78(5):1506-1524.
[17] Chao X, Wang S, Ma X, et al. Persistent mTORC1 activation due to loss of liver tuberous sclerosis complex 1 promotes liver injury in alcoholic hepatitis[J]. Hepatology,2023,78(2):503-517.